ResearchCatalyst analysisKyverna Therapeutics

Kyverna: Can One Miv-cel Infusion Sustain Function Without Chronic Immunotherapy in Refractory Stiff-Person Syndrome?

v2.0 · Copy

In the single-arm KYSA-8 trial, one miv-cel infusion was followed by a large walking signal at one year and most of the 26 treated patients remained off chronic stiff-person syndrome (SPS) immunotherapy.

NNNyochembeng NkengbezaFounder & Research Lead · Published October 23, 2026 · 4 min web summary

CoverageKyverna TherapeuticsLensCatalyst to commercial impactResearch standardEvidence before narrative

Thesis outcome tracking

Published occurrence tracking

These published occurrence records are linked to this exact thesis. A locked occurrence question does not establish a numerical Expected Impact, realized impact, or Catalyst Outcome Grade.

If FDA approves miv-cel for SPS, will treated US patients keep the walking and disability gains seen in KYSA-8, without restarting chronic SPS immunotherapy, in enough numbers and centers to change how refractory SPS is treated?

Occurrence: Unresolved
Record state: Active
Lock date: October 23, 2026
Initial reporting checkpoint: Not published
Next reporting checkpoint: Not published
Evidence date: October 23, 2026

OccurrenceCategorical: Yes, Partial, or NoExpected ImpactLocked from -2 to +2 before realized evidenceRealized ImpactAttributable company-direction effect from -2 to +2Company SignificanceBreadth plus company reach from 0 to 5 stars

A comparison is published only after the thesis reaches its stated evidence and measurement gates.

How grades work

Occurrence

Occurrence is neutral. It records whether the catalyst happened and does not determine the company consequence.

Expected Impact

The forward-locked company-direction expectation is preserved before realized evidence opens.

Realized Impact

Measures the attributable company-direction consequence from operating and commercial evidence, not share-price performance.

Company Significance

Measures breadth and demonstrated company reach. Grade depth is excluded, and unresolved evidence remains off-scale.

A nested comparison is published only when both periods contain the same persistent catalyst set.